Clinical Trials Directory

Trials / Completed

CompletedNCT05547087

A Dose Finding Study of VN-0200

A Phase 2, Randomized, Double-Blind, Dose Finding Study to Describe the Immunogenicity, Safety and Tolerability of VN-0200 in Japanese Adults Aged 60-80 Years

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
342 (actual)
Sponsor
Daiichi Sankyo · Industry
Sex
All
Age
60 Years – 80 Years
Healthy volunteers
Accepted

Summary

This study will assess the immunogenicity, safety and tolerability of VN-0200 after intramuscular injections in Japanese healthy elderly subjects.

Conditions

Interventions

TypeNameDescription
BIOLOGICALVN-0200VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b) administered as an intramuscular injection; 2 shots in 4 weeks.

Timeline

Start date
2022-10-13
Primary completion
2023-04-11
Completion
2024-02-15
First posted
2022-09-21
Last updated
2024-02-29

Locations

3 sites across 1 country: Japan

Source: ClinicalTrials.gov record NCT05547087. Inclusion in this directory is not an endorsement.

A Dose Finding Study of VN-0200 (NCT05547087) · Clinical Trials Directory